CAMBRIDGE, Mass.--(BUSINESS WIRE)--CMO Consulting, Inc. an oncology drug development consulting firm, launched today to provide strategic clinical drug development consulting services to the biopharmaceutical industry. Led by Edward Garmey, M.D., a recognized leader in the field, CMO Consulting applies its extensive medical and industry experience to provide CMO leadership for its clients, including developing and executing clinical strategy while building infrastructure and capacity for the future.
“With our population aging, cancer incidence rates continue to rise. This has led to greatly increased investment in cancer drug development and, with that, the intense demand for experienced oncologists with senior level industry experience,” said Edward Garmey, M.D., President and Founder of CMO Consulting. “CMO Consulting meets these needs by providing its clients with transitional support in the form of senior level medical executives with extensive academic and industry experience. The idea here is to help drug development companies maintain full speed and momentum while they search or prepare for a fulltime CMO.”
With Dr. Garmey already having served as a transitional CMO for a number of leading biotechnology firms, including Bicycle Therapeutics, X4 Pharma, H3 Biomedicine, and Sensei Biotherapeutics, CMO Consulting will formalize a business model that makes sense. According to Sensei CEO, John Celebi, who worked with Dr. Garmey at both Sensei and X4:
“Having Edward work with us at both companies was invaluable. Over approximately six months to a year, he not only interfaced with investigators and KOLs but helped map out and finalize clinical development plans and timelines, while also working hand-in-hand with us on business development and fundraising. In both instances, he also worked to place world-class fulltime CMOs and build clinical infrastructure. I would strongly recommend these services to any company in a similar stage of growth.”
About CMO Consulting Inc.
CMO Consulting is led by Edward Garmey, M.D. a former academic hematologist-oncologist at Memorial Sloan-Kettering Cancer Center with a successful industry track-record comprising over a decade of senior leadership experience including seven prior CMO roles. CMO Consulting provides its clients, ranging from blue-chip venture capital firms to start-ups and established biotechnology companies, with cancer drug development strategy and expertise through every step of pipeline and drug candidate development. For more information visit www.CMOconsulting.com.